BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kee KM, Hung CH, Wang JH, Lu SN. Serial changes of clinical parameters in a patient with advanced hepatocellular carcinoma with portal vein thrombosis achieving complete response after treatment with sorafenib. Onco Targets Ther. 2014;7:829-834. [PMID: 24920924 DOI: 10.2147/ott.s61740] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
Number Citing Articles
1 Pinter M, Sieghart W. Long-term remission in advanced stage hepatocellular carcinoma? A chance for cure? Memo 2018;11:185-92. [PMID: 30220924 DOI: 10.1007/s12254-018-0431-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
2 Zhang YF, Wei W, Wang JH, Xu L, Jian PE, Xiao CZ, Zhong XP, Shi M, Guo RP. Transarterial chemoembolization combined with sorafenib for the treatment of hepatocellular carcinoma with hepatic vein tumor thrombus. Onco Targets Ther 2016;9:4239-46. [PMID: 27471398 DOI: 10.2147/OTT.S106659] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
3 Katafuchi E, Takami Y, Wada Y, Tateishi M, Ryu T, Mikagi K, Saitsu H. Long-Term Maintenance of Complete Response after Sorafenib Treatment for Multiple Lung Metastases from Hepatocellular Carcinoma. Case Rep Gastroenterol. 2015;9:285-290. [PMID: 26351418 DOI: 10.1159/000438746] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
4 Chen J, Yang P, Yang J, Wen Z, Zhang B, Zheng X. GIT1 is a novel prognostic biomarker and facilitates tumor progression via activating ERK/MMP9 signaling in hepatocellular carcinoma. Onco Targets Ther 2015;8:3731-42. [PMID: 26719701 DOI: 10.2147/OTT.S96715] [Cited by in Crossref: 2] [Cited by in F6Publishing: 9] [Article Influence: 0.3] [Reference Citation Analysis]
5 Takano M, Kokudo T, Miyazaki Y, Kageyama Y, Takahashi A, Amikura K, Sakamoto H. Complete response with sorafenib and transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma. World J Gastroenterol 2016; 22(42): 9445-9450 [PMID: 27895433 DOI: 10.3748/wjg.v22.i42.9445] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
6 Xu W, Cheng Y, Tu B. [Construction and validation of a nomogram for predicting the risk of portal vein thrombosis after splenectomy in patients with hepatitis B cirrhosis]. Nan Fang Yi Ke Da Xue Xue Bao 2020;40:1265-72. [PMID: 32990234 DOI: 10.12122/j.issn.1673-4254.2020.09.07] [Reference Citation Analysis]
7 Bertino G, Demma S, Ardiri A, Proiti M, Gruttadauria S, Toro A, Malaguarnera G, Bertino N, Malaguarnera M, Malaguarnera M. Hepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapies. Biomed Res Int. 2014;2014:203693. [PMID: 25089265 DOI: 10.1155/2014/203693] [Cited by in Crossref: 47] [Cited by in F6Publishing: 50] [Article Influence: 5.9] [Reference Citation Analysis]